Research Tracker›Biomarker Atlas›Lyme Disease›C-Reactive Protein (CRP)

C-Reactive Protein (CRP) in Lyme Disease

C-Reactive Protein (CRP), also described as Acute phase protein, is a inflammatory marker reported as elevated in Lyme Disease (Lyme borreliosis, Borrelia burgdorferi infection) when patients are compared with healthy controls. Symptom domains tied to this marker in the source include raised at diagnosis in early Lyme; normalises after treatment. The evidence summarised here comes from Soloski et al. 2014 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedInflammatoryLOINC 1988-5

Summary

Direction in Lyme Disease↑ Elevated — higher than in the comparison group
CategoryInflammatory
Also described asAcute phase protein
Compared againstHC (healthy controls)
Associated symptomsRaised at diagnosis in early Lyme; normalises after treatment
Test typeBlood test (serum / plasma / whole blood)
LOINC code1988-5
SourceSoloski et al. 2014 — doi:10.1371/journal.pone.0093243
Condition atlasLyme Disease Biomarker Atlas

Other conditions where CRP is reported

Atlas entryDirectionCompared against
CRP in Atrial Fibrillation↑ elevatedvs AF vs normal population
CRP in COPD↑ elevatedvs smokers/COPD vs non-smokers
C-Reactive Protein (CRP) in Gulf War Illness↑ elevatedvs HGV
CRP in Inflammatory Bowel Disease (Crohn's/UC)↑ elevatedvs active/moderate-to-severe IBD vs symptomatic remission
C-Reactive Protein (CRP) in Long COVID↑ elevatedvs HC, R
CRP in Low Back Pain↑ elevatedvs nonspecific LBP vs healthy (association evidence)
CRP in Major Depressive Disorder↑ elevatedvs females with depression vs healthy female controls
C-Reactive Protein (CRP) in ME/CFS↕ inconsistentvs HC
CRP in Osteoarthritis↑ elevatedvs OA vs healthy (elevated but less than RA)
CRP in Rheumatoid Arthritis↑ elevatedvs RA vs healthy (acute phase reactant, classification criterion)

See the cross-condition hub: CRP across conditions.

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term C-reactive protein (CRP) (20 registered trials use a matching outcome measure).

Clinical trials using C-Reactive Protein (CRP) as an outcome

NCT05703074Completed
Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid
Outcome measure: Inflammation
NCT05524532Completed
Effects of Immulina TM Supplements With PASC Patients
Outcome measure: Plasma CRP (C-Reactive Protein, ng/mL)
NCT06142253Recruiting
Water-based Activity to Enhance Recovery in Long COVID-19
Outcome measure: Change in Blood labs
NCT06597396Active Not Recruiting
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
Outcome measure: The difference in blood high sensitivity C-reactive protein (HSCRP) from baseline visit to Day 84
NCT06437223Completed
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
Outcome measure: Secondary Endpoint
NCT07285707Recruiting
Acupuncture and Chinese Herbal Medicine for Long COVID
Outcome measure: Change in Laboratory Biomarkers - C-reactive protein
NCT05877508Active Not Recruiting
Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
Outcome measure: C-Reactive Protein (CRP)
NCT05836402Completed
Long COVID-19 Syndrome Lifestyle Intervention Study
Outcome measure: Improvement of long-COVID syndrome signs: Measures of inflammation

12 more trials reference this marker.

Interventions studied alongside this marker

Hypothesis-generating links from trial outcome usage and literature co-occurrence. Not treatment recommendations.

Commercial test availability

C-Reactive Protein (CRP) — commercial laboratory test.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related Inflammatory markers in Lyme Disease

Full list: Lyme Disease Biomarker Atlas.

Frequently asked questions

Is C-Reactive Protein (CRP) high or low in Lyme Disease?

Elevated. Studies summarised in the OSMF atlas report higher C-Reactive Protein (CRP) in Lyme Disease than in healthy controls. Source: Soloski et al. 2014.

What symptoms is C-Reactive Protein (CRP) associated with in Lyme Disease?

The cited literature associates this marker with Raised at diagnosis in early Lyme; normalises after treatment. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures C-Reactive Protein (CRP)?

It is measured as a blood test (serum / plasma / whole blood). The standard laboratory code is LOINC 1988-5. Commercial laboratories such as Quest Diagnostics, LabCorp, Ulta Lab Tests list an orderable assay.

Is one abnormal C-Reactive Protein (CRP) result diagnostic of Lyme Disease?

No. No single biomarker is diagnostic of Lyme Disease. C-Reactive Protein (CRP) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is C-Reactive Protein (CRP) specific to Lyme Disease?

No. The same marker is also reported in Atrial Fibrillation, COPD, Gulf War Illness, Inflammatory Bowel Disease (Crohn's/UC), Long COVID, Low Back Pain, ME/CFS, Major Depressive Disorder, Osteoarthritis, Rheumatoid Arthritis in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). C-Reactive Protein (CRP) in Lyme Disease: direction, evidence and what it means. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/lyme/c-reactive-protein-crp.html

Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.